You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Both tests can detect SARS-CoV-2 in 90 minutes and will detect viruses like influenza and respiratory syncytial virus that tend to occur in the winter.
The panel tests for 23 pathogens covering 19 viruses, including SARS-CoV-2, and four bacteria that are responsible for the most frequent respiratory infections.
The better-than-expected sales growth reflects "very significant demand" for COVID-19 testing products, tempered by weaker customer demand in other product areas.
The real-time RT-PCR multiplex test is intended for the simultaneous detection and differentiation of SARS-CoV-2, influenza A virus, and influenza B virus.
The company's revenue growth was driven by increasing sales of its ePlex molecular diagnostics analyzer, which now has a SARS-CoV-2 test.
The PCR tests are being requested more often during the SARS-CoV-2 pandemic to rule out patients with other viral respiratory conditions.
The firm believes that its molecular assay for the laboratory will help ease some of the supply chain issues hampering test rollout during the pandemic.
The test, developed by the firms in six weeks, is part of a viral respiratory panel and runs on Bosch's point-of-care Vivalytic system.
The panel can detect and differentiate SARS-CoV-2 and 20 other pathogens known to cause serious respiratory disease from nasopharyngeal swabs in symptomatic patients.
The firm now expects to complete the development work needed to request Emergency Use Authorization for the new panel.